Key Drivers
- Margin Recovery
- Cash Burn
- Dilution Risk
AIAI Summary
BFLY is best viewed as a venture-like imaging platform rather than a mature medtech company: improving core revenue and 71% gross margins support upside, but its premium valuation depends on unproven Embedded, AI, and licensing monetization while cash burn remains substantial. Investors should wait for evidence of declining cash burn and disclosed recurring partner economics before underwriting the platform premium.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Recovery
- •Cash Burn
- •Dilution Risk
BFLY's profitability and liquidity improved materially, but persistent cash burn, dilution risk, weak capital efficiency, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •Support defended
- •Resistance overhead
BFLY remains bearish over the last month, with support at $7.10–$7.30 and a stronger outlook only if it sustains above $8.03–$8.20.
Sharp decline from $9.55 to $7.12 highlights elevated volatility
Sentiment & News
Key News Insights:
- •AI Ultrasound Deal
- •Investor Conference
- •Mixed Insider Trades
Butterfly Network's AI-enabled ultrasound expansion and conference visibility strengthen its growth narrative, though mixed insider trading warrants monitoring.
The news is moderately positive for Butterfly's strategic positioning, with insider activity presenting a minor caution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings